Antipsychotics and Amotivation

Neuropsychopharmacology

Volumn 40, Issue 6, 2015, Pages 1539-1548

  Fervaha, Gagan ^a,b   Takeuchi, Hiroyoshi ^a,c   Lee, Jimmy ^a,c   Foussias, George ^a,b,c   Fletcher, Paul J ^a,c   Agid, Ofer ^a,b,c   Remington, Gary ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MOTIVATION; MULTICENTER STUDY; PSYCHOLOGIC TEST; PSYCHOLOGY; QUALITY OF LIFE; SCHIZOPHRENIA; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOTIVATION; PSYCHOLOGICAL TESTS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; UNITED STATES; YOUNG ADULT;

EID: 84940006894     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.3     Document Type: Article

References (63)

1. Addington D, Addington J, Maticka-Tyndale E, Joyce J (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 6: 201-208.
2. Amato D, Natesan S, Yavich L, Kapur S, Muller CP (2011). Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment. Int J Neuropsychopharmacol 14: 1327-1339.
3. Appelbaum PS, Grisso T (2001). MacArthur competence assessment tool for clinical research (MacCAT-CR). Professional Resource Press: Sarasota, FL.
4. Artaloytia JF, Arango C, Lahti A, Sanz J, Pascual A, Cubero P et al (2006). Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry 163: 488-493.
5. Barch DM, Dowd EC (2010). Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions. Schizophr Bull 36: 919-934.
6. Bedard AM, Maheux J, Levesque D, Samaha AN (2011). Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues. Neuropsychopharmacology 36: 1248-1259.
7. Blanchard JJ, Cohen AS (2006). The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull 32: 238-245.
8. Bleuler E (1950). Dementia Praecox or the group of schizophrenias. International Universities Press: New York.
9. Bobes J, Arango C, Garcia-Garcia M, Rejas J (2010). Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry 71: 280-286.
10. Breier A, Wolkowitz OM, Doran AR, Roy A, Boronow J, Hommer DW et al (1987). Neuroleptic responsivity of negative and positive symptoms in schizophrenia. Am J Psychiatry 144: 1549-1555.
11. Carpenter WT Jr., Heinrichs DW, Wagman AM (1988). Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 145: 578-583.
12. Choi KH, Fiszdon JM, Bell MD (2013). Beyond cognition: a longitudinal investigation of the role of motivation during a vocational rehabilitation program. J Nerv Ment Dis 201: 173-178.
13. de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D (2003). Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry 160: 303-309.
14. Faerden A, Nesvag R, Barrett EA, Agartz I, Finset A, Friis S et al (2008). Assessing apathy: the use of the Apathy Evaluation Scale in first episode psychosis. Eur Psychiatry 23: 33-39.
15. Farde L, Wiesel FA, Halldin C, Sedvall G (1988). Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71-76.
16. Fervaha G, Foussias G, Agid O, Remington G (2014). Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia. Acta Psychiatr Scand 130: 290-299.
17. Fervaha G, Foussias G, Agid O, Remington G (2013a). Neural substrates of effort computation in schizophrenia. Neurosci Biobehav Rev 37: 2649-2665.
18. Fervaha G, Graff-Guerrero A, Zakzanis KK, Foussias G, Agid O, Remington G (2013b). Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making. J Psychiatr Res 47: 1590-1596.
19. First MB (1997). User's guide for the Structured clinical interview for DSM-IV axis I disorders SCID-I: clinician version . Amer Psychiatric Pub Inc: Washington, DC.
20. Gard DE, Fisher M, Garrett C, Genevsky A, Vinogradov S (2009). Motivation and its relationship to neurocognition, social cognition, and functional outcome in schizophrenia. Schizophr Res 115: 74-81.
21. Gold JM, Strauss GP, Waltz JA, Robinson BM, Brown JK, Frank MJ (2013). Negative symptoms of schizophrenia are associated with abnormal effort-cost computations. Biol Psychiatry 74: 130-136.
22. Hartmann MN, Hager OM, Reimann AV, Chumbley JR, Kirschner M, Seifritz E et al (22 July 2014). Apathy but not diminished expression in schizophrenia is associated with discounting of monetary rewards by physical effort. Schizophr Bull; e-pub ahead of print..
23. Harvey PD, Davidson M, White L, Keefe RS, Hirschowitz J, Mohs RC et al (1996). Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale. Biol Psychiatry 40: 755-760.
24. Heinrichs DW, Hanlon TE, Carpenter WT Jr. (1984). The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10: 388-398.
25. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A et al (2012). The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies. Arch Gen Psychiatry 69: 776-786.
26. Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wustenberg T, Villringer A et al (2006). Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl) 187: 222-228.
27. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
28. Kelley ME, van Kammen DP, Allen DN (1999). Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am J Psychiatry 156: 406-411.
29. Kraepelin E (1919). Dementia Praecox and Paraphrenia. Livingstone: Edinburgh, UK.
30. Lahti AC, Weiler MA, Holcomb HH, Tamminga CA, Cropsey KL (2009). Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia. Neuropsychopharmacology 34: 2675-2690.
31. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009). How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14: 429-447.
32. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl JMed 353: 1209-1223.
33. Liemburg E, Castelein S, Stewart R, van der Gaag M, Aleman A, Knegtering H (2013). Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. J Psychiatr Res 47: 718-725.
34. Mas S, Gasso P, Fernandez de Bobadilla R, Arnaiz JA, Bernardo M, Lafuente A (2013). Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial. Hum Psychopharmacol 28: 586-593.
35. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al (2006). Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163: 790-799.
36. Miller DD, Flaum M, Arndt S, Fleming F, Andreasen NC (1994). Effect of antipsychotic withdrawal on negative symptoms in schizophrenia. Neuropsychopharmacology 11: 11-20.
37. Mizrahi R, Rusjan P, Agid O, Graff A, Mamo DC, Zipursky RB et al (2007). Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry 164: 630-637.
38. Nakagami E, Hoe M, Brekke JS (2010). The prospective relationships among intrinsic motivation, neurocognition, and psychosocial functioning in schizophrenia. Schizophr Bull 36: 935-948.
39. Nakagami E, Xie B, Hoe M, Brekke JS (2008). Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: testing mediator and moderator effects. Schizophr Res 105: 95-104.
40. Nielsen MO, Rostrup E, Wulff S, Bak N, Broberg BV, Lublin H et al (2012). Improvement of Brain Reward Abnormalities by Antipsychotic Monotherapy in Schizophrenia. Arch Gen Psychiatry 69: 1195-1204.
41. Park CH, Park TW, Yang JC, Lee KH, Huang GB, Tong Z et al (2012). No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial. Int Clin Psychopharmacol 27: 114-120.
42. Peralta V, Cuesta MJ, Martinez-Larrea A, Serrano JF (2000). Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment. Am J Psychiatry 157: 1461-1466.
43. Piskulic D, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R et al (2012). Negative symptoms in individuals at clinical high risk of psychosis. Psychiatry Res 196: 220-224.
44. Prosser ES, Csernansky JG, Kaplan J, Thiemann S, Becker TJ, Hollister LE (1987). Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics. J Nerv Ment Dis 175: 100-105.
45. Rifkin A (1975). Akinesia: a poorly recognized drug-induced extrapyramidal behavioral disorder. Arch Gen Psychiatry 32: 672-674.
46. Saeedi H, Remington G, Christensen BK (2006). Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res 85: 222-231.
47. Salamone JD, Correa M (2012). The mysterious motivational functions of mesolimbic dopamine. Neuron 76: 470-485.
48. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S (2007). 'Breakthrough' dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27: 2979-2986.
49. Saperstein AM, Fiszdon JM, Bell MD (2011). Intrinsic motivation as a predictor of work outcome after vocational rehabilitation in schizophrenia. J Nerv Ment Dis 199: 672-677.
50. Sayers SL, Curran PJ, Mueser KT (1996). Factor structure and construct validity of the Scale for the Assessment of Negative Symptoms. Psychol Assess 8: 269.
51. Schooler NR (1994). Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits. Acta Psychiatr Scand Suppl 380: 21-26.
52. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212: 11-19.
53. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM et al (2003). The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 29: 15-31.
54. Tollefson GD, Sanger TM (1997). Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154: 466-474.
55. Tracy K, Adler LA, Rotrosen J, Edson R, Lavori P (1997). Interrater reliability issues in multicenter trials, Part I: Theoretical concepts and operational procedures used in Department of Veterans Affairs Cooperative Study #394. Psychopharmacol Bull 33: 53-57.
56. Trifilieff P, Feng B, Urizar E, Winiger V, Ward RD, Taylor KM et al (2013). Increasing dopamine D2 receptor expression in the adult nucleus accumbens enhances motivation. Mol Psychiatry 18: 1025-1033.
57. Tugg LA, Desai D, Prendergast P, Remington G, Reed K, Zipursky RB (1997). Relationship between negative symptoms in chronic schizophrenia and neuroleptic dose, plasma levels and side effects. Schizophr Res 25: 71-78.
58. Vogel SJ, Strauss GP, Allen DN (2013). Using negative feedback to guide behavior: impairments on the first 4 cards of the Wisconsin Card Sorting Test predict negative symptoms of schizophrenia. Schizophr Res 151: 97-101.
59. Vohs JL, Lysaker PH, Nabors L (2013). Associations of personalitywith intrinsic motivation in schizophrenia. Psychiatry Res 208: 78-80.
60. Waltz JA, Frank MJ, Wiecki TV, Gold JM (2011). Altered probabilistic learning and response biases in schizophrenia: behavioral evidence and neurocomputational modeling Neuropsychology 25: 86-97.
61. Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Weinberger DR (2003). Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology 28: 1491-1500.
62. Wolf DH, Satterthwaite TD, Kantrowitz JJ, Katchmar N, Vandekar L, Elliott MA et al (2014). Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures. Schizophr Bull 40: 1328-1337.
63. Yamada AM, Lee KK, Dinh TQ, Barrio C, Brekke JS (2010). Intrinsic motivation as a mediator of relationships between symptoms and functioning among individuals with schizophrenia spectrum disorders in a diverse urban community. J Nerv Ment Dis 198: 28-34.